Clinical and pre-clinical data
First route to market presented in AML
2L relapsed AML chosen as ideal path to registration
Potential pivotal study to start in 2021
06 Nov 2020
R&D Day Highlights with path to market
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
R&D Day Highlights with path to market
Clinical and pre-clinical data
First route to market presented in AML
2L relapsed AML chosen as ideal path to registration
Potential pivotal study to start in 2021